Thoracic Surgery Department, Guy's Hospital, London, United Kingdom.
Department of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
J Thorac Oncol. 2024 Sep;19(9):1326-1338. doi: 10.1016/j.jtho.2024.05.003. Epub 2024 May 9.
The International Association for the Study of Lung Cancer developed an international database to inform potential revisions in the ninth edition of the TNM classification of diffuse pleural mesothelioma (PM). This study analyzed the clinical and pathologic N categories to determine whether revisions were indicated relative to the eighth edition staging system.
Of 7338 PM cases diagnosed from 2013 to 2022 and 3598 met all inclusion criteria for planned analyses. Data on 2836 patients without metastases were included in this study. Overall survival (OS) was measured from date of diagnosis. Patients were included regardless of whether they received neoadjuvant treatment. For the pathologic N analysis, patients who underwent resection (extrapleural pneumonectomy or pleurectomy/decortication) were included. N subgroups were analyzed and OS assessed by the Kaplan-Meier method.
The existing eighth edition N categories were performed adequately in the ninth edition data set. A median OS advantage was noted for clinical and pathologic N0 versus N1 patients: 23.2 versus 18.5 and 33.8 versus 25.0 months, respectively. Patients with resected pN0 had a 3-year OS of 48%. No difference in OS was noted for single- versus multiple-station nodal metastases. The number of nodal stations sampled at the time of resection was not associated with a difference in OS.
Data regarding clinical and pathologic N categories corroborate those used in the eighth edition. No changes in the N categories are recommended in the ninth edition of PM staging system.
国际肺癌研究协会(IASLC)开发了一个国际数据库,旨在为第九版弥漫性胸膜间皮瘤(PM)的 TNM 分类修订提供信息。本研究分析了临床和病理 N 分期,以确定相对于第八版分期系统是否需要进行修订。
在 2013 年至 2022 年间诊断的 7338 例 PM 病例中,有 3598 例符合计划分析的所有纳入标准。本研究纳入了 2836 例无转移的患者。总生存期(OS)从诊断日期开始计算。无论患者是否接受新辅助治疗,均纳入本研究。对于病理 N 分析,纳入接受了胸膜外全肺切除术或胸膜/肺切除术的患者。分析了 N 亚组,并通过 Kaplan-Meier 方法评估 OS。
在第九版数据集的现有第八版 N 分期中表现良好。临床和病理 N0 与 N1 患者的 OS 优势明显:23.2 个月与 18.5 个月和 33.8 个月与 25.0 个月。接受根治性切除的 pN0 患者的 3 年 OS 为 48%。单一和多个淋巴结转移部位的 OS 无差异。在根治性切除时采样的淋巴结站数量与 OS 无差异。
临床和病理 N 分期的数据与第八版使用的数据一致。在第九版 PM 分期系统中,不建议对 N 分期进行修改。